Burnett-Bowie et al. investigated the efficacy and safety of the synthetic aromatase inhibitor anastrozole to treat hypogonadism in aging men. The study enrolled 88 men (60 years or older ...

[5] Early adjuvant therapy -- replacing tamoxifen therapy with aromatase inhibitor therapy during the first 5 years after surgery; Early sequential adjuvant therapy -- sequencing of tamoxifen and ...

Aromatase inhibitors are able to block the biosynthesis of estrogen—a process that is essential in bone maturation, growth-plate fusion, and cessation of longitudinal growth. Aromatase ...

Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

Novartis (NVS) announced that the European Commission, EC, has approved Kisqali in combination with an aromatase inhibitor, AI, for the ...

The European Commission (EC) has granted approval to Novartis' Kisqali (ribociclib), plus an aromatase inhibitor to treat ...

Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of ...

The European Commission has cleared use of CDK4/6 inhibitor Kisqali (ribociclib) to reduce the risk of recurrence in patients ...

(RTTNews) - Novartis (NVS) said that the European Commission has approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor ...